Francois-alexandre A. Buteau
Quebec, QC, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Trajectory timelines and treatment efficacy of 177Lu-PSMA-617 radioligand therapy for metastatic castration-resistant prostate cancer Real-world data from 50 consecutive cases treated in a single Canadian center.
Journal: Canadian Urological Association journal = Journal de l'Association des urologues du Canada
Published: February 17, 2026
The tumour sink effect on 68Ga-PSMA-PET/CT in metastatic castration-resistant prostate cancer and its implications for PSMA-RPT: a sub-analysis of the 3TMPO study.
Journal: Cancer imaging : the official publication of the International Cancer Imaging Society
Published: May 22, 2025
Utility of 18F-FDG PET/CT in the Surveillance of Patients With Neurofibromatosis Type 1.
Journal: Neurology. Genetics
Published: May 16, 2025
Intrapatient Intermetastatic Heterogeneity Determined by Triple-Tracer PET Imaging in mCRPC Patients and Correlation to Survival: The 3TMPO Cohort Study.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: May 31, 2024
Highly Symptomatic Progressing Cardiac Paraganglioma With Intracardiac Extension Treated With 177Lu-DOTATATE: A Case Report.
Journal: Frontiers in endocrinology
Published: May 05, 2021
18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) is accurate for high-grade prostate cancer bone staging when compared to bone scintigraphy.
Journal: Canadian Urological Association journal = Journal de l'Association des urologues du Canada
Published: March 22, 2021
GLUT1 expression in high-risk prostate cancer: correlation with 18F-FDG-PET/CT and clinical outcome.
GLUT1 expression in high-risk prostate cancer: correlation with 18F-FDG-PET/CT and clinical outcome.
Journal: Prostate cancer and prostatic diseases
Published: October 24, 2019
Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial.
Journal: European journal of nuclear medicine and molecular imaging
Published: July 24, 2018
Accuracy and reproducibility of simplified QSPECT dosimetry for personalized 177Lu-octreotate PRRT.
Journal: EJNMMI physics
Published: April 04, 2018
Increased Prostate Cancer Glucose Metabolism Detected by 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Localised Gleason 8-10 Prostate Cancers Identifies Very High-risk Patients for Early Recurrence and Resistance to Castration.
Journal: European urology focus
Published: January 12, 2018
Neuroradiological and Neuropathological Changes After 177Lu-Octreotate Peptide Receptor Radionuclide Therapy of Refractory Esthesioneuroblastoma.
Journal: Operative neurosurgery (Hagerstown, Md.)
Published: January 10, 2018
Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study.
Journal: European journal of nuclear medicine and molecular imaging
Published: October 21, 2016
Last Updated: 09/26/2026